No Data
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12
Loss-Making Avadel Pharmaceuticals Plc (NASDAQ:AVDL) Expected To Breakeven In The Medium-Term
Avadel Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Raises Target Price to $30
Express News | Avadel Pharmaceuticals PLC - Lumryz Approval Upheld Based on Clinical Superiority
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
No Data
No Data